SCHEMBL1945889

SCHEMBL1945889

Cc1cc(S(=O)(=O)Nc2cccc(CCc3ccccn3)c2)c(C)o1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.63
MAPT P10636 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.60
HTT P42858 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
HTR6 P50406 4/20 0.44
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
IDH1 O75874 2/20 0.39
CYP2D6 P10635 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945957 0.83 HSD11B1 (0.66) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1947283 0.82 HSD11B1 (0.64) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1947196 0.81 HSD11B1 (0.63) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1947915 0.80 MAPT (0.72) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1946616 0.79 MAPT (0.64) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL12563556 0.79 HSD11B1 (0.80) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1944991 0.78 SMN1; SMN2 (0.74) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1946486 0.77 HSD11B1 (0.58) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL1948063 0.77 HSD11B1 (0.69) HSD11B1MAPTSMN1; SMN2HTTNPSR1
SCHEMBL9886550 0.76 HSD11B1 (0.60) HSD11B1MAPTSMN1; SMN2HTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130426-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 HSD11B1 16/4885MAPT 3552/4885SMN1; SMN2 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.